SALT LAKE CITY, July 6 /PRNewswire/ -- ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced today the appointment of Sherrie L. Perkins, MD, PhD, as chief medical officer (CMO) and director of laboratories, effective, July 1, 2009.
Dr. Perkins will be taking over the responsibility from Edward R. Ashwood, MD, who will be transitioning into the role of president and chief executive officer. These transitions will coincide with the announced retirement of ARUP founder and CEO Carl R. Kjeldsberg, MD, on June 30, 2009.
"Dr. Perkins is uniquely qualified to lead ARUP into the future. She has shown superb leadership and a commitment to advancing patient care through laboratory medicine," said Dr. Ashwood.
Dr. Perkins has been with ARUP Laboratories and the University of Utah for 19 years. During this time, she has served in numerous leadership roles including director of hematopathology, interim department chair, and, for the past three years, as a member of the ARUP Laboratories executive management team. She is a tenured professor at the University of Utah School of Medicine, is board certified in anatomic pathology and holds a special qualification in hematology.
Dr. Perkins received her PhD in biochemistry from the University of Miami. She earned her MD and completed her pathology residency at Washington University.
"ARUP has a distinguished history of improving patient care, research, and medical education. I look forward to working with my colleagues to build upon this history," remarked Dr. Perkins.
About ARUP Laboratories
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and an enterprise of the University of Utah and its Department of Pathology. With Page: 1 2 Related medicine news :1
. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2010 First Quarter Earnings2
. Caraco Pharmaceutical Laboratories, Ltd. Announces an Indefinite Reduction in its Workforce3
. Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position4
. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action5
. Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization6
. AirClic Mobile Business Solutions Clic for Bio-Reference Laboratories, Inc.7
. M.A.Z.E. Cord Blood Laboratories Offers Expectant Parents The Chance To Win A $500 Savings Bond8
. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection9
. IDEXX Laboratories to Present at William Blair 29th Annual Growth Stock Conference10
. Underwriters Laboratories Reminds Parents to Pay Attention to Staycation Safety Hazards11
. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Roxicodone(R) Tablets